index.php?vrs=hemarina_francais
Send this article to a friend Print the page 

viadeo-hemarina facebook-hemarina flux rss hemarina linked in hemarina

Board of Directors

Home > Corporate > Board of Directors



Franck Zal,
Ph.D. - HDR - MBA
Chairman of the Board



Dr. Franck Zal
, Co-founder of the company, brings his internationally recognized scientific expertise to the field of the respiratory pigments of invertebrates. After his Ph.D. he spent three years abroad, two years at the University of Santa Barbara in California (USA) and one year at the University of Antwerp (Belgium). Franck, is the author of over 70 publications in international peer reviewed scientific journals, the author of many patents and he presented his work in numerous international meetings.
   
Francois Thomas
Jean-Briac Lesné
Board member

 

Jean- Briac Lesné started his professional career in the Life Sciences Venture Capital team of Omnes Capital. Afterwards, he worked for Hyperion CD, an M&A and licensing advisory company dedicated to life Sciences industries. In early 2015, he joined the management team of Inserm Transfert Initiative as analyst and associate.
Jean-Briac holds a Pharm.D. from Rennes University and graduated from ESCP – Europe Business School.

   

Patrick Franchet
Board member
 


Patrick Franchet, Finistère Angels past President, sold his accounting and audit company CEGEX to In Extenso (Deloitte). He has been a consultant to a number of companies and was involved in many Boards of Directors of associations related to the economic development . Patrick also taught at the Institute of Business Administration of the University of Western Brittany (UBO). 
At present,  he focuses  on developing  family business in Canada, in the fields of  hotel business, nursing homes and real estate.
  

 
   
Emilie Lidome
Emilie Lidome
Board member

Emilie Lidome is both bio-engineering and business management experienced. She joined the venture capital industry in 2008. Investments director at CM-CIC Innovation, subsidiary of the equity financing arm of the Crédit Mutuel-CIC group, she makes venture capital investments in promising high-tech companies.
Before joining CM-CIC Innovation, Emilie held several positions related to projects management in clinical research and coordination among business lines in pharmaceutical as well as biotechnology industries (Novartis, GSK).
Emilie is graduate biologÂTø engineer of the University of Technology of Compiègne and holds a Grenoble Management School master's degree in biotechnology business management.
   
 
Xavier
Guille des Buttes
Board member

 Xavier Guille des Buttes, graduated from the ESSCA (l’Ecole Supérieure des Sciences Commerciales d’Angers), from the Institute of Foreign Commerce and from the Management Control Institute,  has spent his entire career in the pharmaceutical industry. He has held a large number of executive positions for more than 30 years, particularly in the French subsidiary of the German Group Schering AG, where he has successively held the positions of Marketing Director, General Manager of the pharmaceutical Division and Chairman of the Board of Directors until June 2006.
Member of Genfit’s Supervisory Board since October 2006, he currently chairs the Supervisory Board. In addition to his responsibilities at Genfit, he also serves as a corporate director of several companies. Xavier is member of Hemarina's Board since June 2013.
Xavier also chairs the UCL Foundation (Higher education sector, Lille) and is a knight of the Legion of Honour.
   
   


Corporate
Technology & Products
Intellectual Property
Investors News & Media

>> Company Overview
>> Managment Team
>> Board of Directors
>> Scientific and Ethics Board
>> Hemarina Label and Public Funding

>> Organ Preservation
>> Wound Healing
>> Hemoglobin Oxygen-Carrier
>> Cell Culture and  Bioproduction
>> Other Perspective


>> Portfolio
>> Literature References

 

>> News
>>
Hemarina Awards
>>
Press Releases
>>
Video Releases
>> 2013